Treatment options in Huntington's disease

Bibliography

• Huntington G. On chorea. Med Surg Rep 1872;26(15):317-21
   Google Scholar
• Huntington G. On chorea. George Huntington, M.D. J Neuropsychiatry Clin Neurosci 2003;15(1):109-12
   PubMed Web of Science ®Google Scholar
• Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 2003;74(1):120-2
   PubMed Web of Science ®Google Scholar
• Nehl C, Paulsen JS. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis 2004;192(1):72-4
   PubMed Web of Science ®Google Scholar
• Williams JK, Barnette JJ, Reed D, et al. Development of the Huntington disease family concerns and strategies survey from focus group data. J Nurs Meas 2010;18(2):83-99
   PubMedGoogle Scholar
• Paulsen JS, Zhao H, Stout JC, et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 2001;57(4):658-62
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63(6):883-90
   PubMedGoogle Scholar
• Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008;79(8):874-80
   PubMed Web of Science ®Google Scholar
• Johnson SA, Stout JC, Solomon AC, et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 2007;130(Pt 7):1732-44
   PubMedGoogle Scholar
• Snowden JS, Austin NA, Sembi S, et al. Emotion recognition in Huntington's disease and frontotemporal dementia. Neuropsychologia 2008;46(11):2638-49
   PubMed Web of Science ®Google Scholar
• Henley SM, Wild EJ, Hobbs NZ, et al. Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia 2008;46(8):2152-60
   PubMed Web of Science ®Google Scholar
• de Gelder B, Van den Stock J, Balaguer Rde D, et al. Huntington's disease impairs recognition of angry and instrumental body language. Neuropsychologia 2008;46(1):369-73
   PubMed Web of Science ®Google Scholar
• Calder A, Keane J, Young A, et al. The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease. Neuropsychologia 2010;48(9):2719-29
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10(1):31-42
   PubMed Web of Science ®Google Scholar
• Hinton SC, Paulsen JS, Hoffmann RG, et al. Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc 2007;13(3):539-43
   PubMed Web of Science ®Google Scholar
• Zimbelman JL, Paulsen JS, Mikos A, et al. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc 2007;13(5):758-69
   PubMed Web of Science ®Google Scholar
• Rowe KC, Paulsen JS, Langbehn DR, et al. Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 2010;24(4):435-42
   PubMed Web of Science ®Google Scholar
• Almqvist EW, Bloch M, Brinkman R, et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 1999;64(5):1293-304
   PubMed Web of Science ®Google Scholar
• Penney JB Jr, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41(5):689-92
   PubMed Web of Science ®Google Scholar
• Vonsattel JP, Keller C, Cortes Ramirez EP. Huntington's disease - neuropathology. Handb Clin Neurol 2011;100:83-100
   PubMedGoogle Scholar
• Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983;306(5940):234-8
   PubMed Web of Science ®Google Scholar
• The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72(6):971-83
   PubMed Web of Science ®Google Scholar
• Gusella JF, MacDonald ME. Hunting for Huntington's disease. Mol Genet Med 1993;3:139-58
   PubMedGoogle Scholar
• Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 2004;101(10):3498-503
   PubMed Web of Science ®Google Scholar
• Ross CA. Huntington's disease: new paths to pathogenesis. Cell 2004;118(1):4-7
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006;12(21):2701-20
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother 2007;8(2):141-53
   PubMed Web of Science ®Google Scholar
• Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008;5(2):181-97
   PubMed Web of Science ®Google Scholar
• Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009(3):CD006456
   Google Scholar
• Setter SM, Neumiller JJ, Dobbins EK, et al. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. Consult Pharm 2009;24(7):524-37
   PubMedGoogle Scholar
• Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66(3):366-72
   PubMed Web of Science ®Google Scholar
• Tetrabenazine (Xenazine) for Huntington's chorea. Med Lett Drugs Ther 2009;51(1304):7-8
   PubMed Web of Science ®Google Scholar
• Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot open label study. Tremor Other Hyperkinet Mov (NY) 2012;2
   Google Scholar
• Nash MC, Ferrell RB, Lombardo MA, et al.Treatment of bruxism in Huntington's disease with botulinum toxin. J Neuropsychiatry Clin Neurosci 2004;16(3):381-2
   PubMed Web of Science ®Google Scholar
• Huys D, Bartsch C, Poppe P, et al. Management and outcome of pallidal deep brain stimulation in severe Huntington's disease. Fortschr Neurol Psychiatr 2013;81(4):202-5
   PubMed Web of Science ®Google Scholar
• Velez-Lago FM, Thompson A, Oyama G, et al. Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington's Disease. Stereotact Funct Neurosurg 2013;91(2):129-33
   PubMed Web of Science ®Google Scholar
• de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10(12):1049-57
   PubMed Web of Science ®Google Scholar
• Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol 2010;33(5):260-4
   PubMed Web of Science ®Google Scholar
• Kara E, Lin H, Svensson K, Johansson AM. Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol 2010;161(6):1343-50
   PubMed Web of Science ®Google Scholar
• Ponten H, Kullingsjo J, Lagerkvist S, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 2010;644(1-3):88-95
   PubMed Web of Science ®Google Scholar
• Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord 2013;28(10):1407-15
   PubMed Web of Science ®Google Scholar
• de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord 2004;19(12):1516-18
   PubMed Web of Science ®Google Scholar
• Epping EA, Paulsen JS. Depression in the early stages of Huntington disease. Neurodegener Dis Manag 1986;1(5):407-14
   Google Scholar
• Ford MF. Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. Br J Psychiatry 1986;149:654-6
   PubMed Web of Science ®Google Scholar
• Rowe KC, Paulsen JS, Langbehn DR, et al. Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res 2010;196(2-3):309-14
   Web of Science ®Google Scholar
• Grote HE, Bull ND, Howard ML, et al. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 2005;22(8):2081-8
   PubMed Web of Science ®Google Scholar
• Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol 2010;25(1):46-50
   PubMed Web of Science ®Google Scholar
• Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 2004;55(4):590-4
   PubMed Web of Science ®Google Scholar
• Reedeker N, Bouwens JA, Giltay EJ, et al. Irritability in Huntington's disease. Psychiatry Res 2012;200(2-3):813-18
   PubMed Web of Science ®Google Scholar
• Singer C. Comprehensive treatment of Huntington disease and other choreic disorders. Cleve Clin J Med 2012;79:S30-4
   PubMedGoogle Scholar
• Bhandary A, Masand P. Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. Psychosomatics 1997;38(4):389-91
   PubMed Web of Science ®Google Scholar
• Byrne A, Martin W, Hnatko G. Beneficial effects of buspirone therapy in Huntington's disease. Am J Psychiatry 1994;151(7):1097
   PubMed Web of Science ®Google Scholar
• Findling RL. Treatment of aggression in juvenile-onset Huntington's disease with buspirone. Psychosomatics 1993;34(5):460-1
   PubMed Web of Science ®Google Scholar
• Kremer B, Clark C, Almqvist E, et al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999;53(5):1000-11
   PubMed Web of Science ®Google Scholar
• Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997;20(2):427-51
   PubMed Web of Science ®Google Scholar
• Roulet E, Deonna T. Successful treatment of hereditary dominant chorea with carbamazepine. Pediatrics 1989;83(6):1077
   PubMed Web of Science ®Google Scholar
• Grove VE Jr, Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000;343(13):973-4
   PubMed Web of Science ®Google Scholar
• Rask G, Andersson C. Good effect of valproate against aggression in Huntington disease. Only two cases reported earlier. Lakartidningen 2010;107(48):3060-1
   PubMedGoogle Scholar
• Tremolizzo L, Rodriguez-Menendez V, DiFrancesco JC, et al. Huntington's disease and HDACi: would sulpiride and valproate be of therapeutic value? Med Hypotheses 2007;69(4):964-5
   PubMed Web of Science ®Google Scholar
• Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2006;18(4):553-4
   PubMed Web of Science ®Google Scholar
• Jhanjee A, Anand K, Bajaj B. Hypersexual features in Huntington's disease. Singapore Med J 2011;52(6):131-3
   PubMed Web of Science ®Google Scholar
• Lopez-Sendon JL, Royuela A, Trigo P, et al. What is the impact of education on Huntington's disease? Mov Disord 2011;26(8):1489-95
   PubMed Web of Science ®Google Scholar
• Dunkel P, Chai C, Sperlágh B, et al. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs 2012;21(9):1267-308
   PubMed Web of Science ®Google Scholar
• Ha A, Fung V. Huntington's disease. Curr Opin Neurol 2012;25(4):491-8
   PubMed Web of Science ®Google Scholar
• Doria JG, Silva FR, de Souza JM, et al. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease. Br J Pharmacol 2013;169(4):909-21
   PubMed Web of Science ®Google Scholar
• Ruiz C, Casarejos MJ, Rubio I, et al. The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins. Brain Res 2012;1459:100-12
   PubMed Web of Science ®Google Scholar
• Valdeolivas S, Satta V, Pertwee R. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB(1) and CB(2) receptors. ACS Chem Neurosci 2012;3(5):400-6
   PubMed Web of Science ®Google Scholar
• Giampa C, Montagna E, Dato C, et al. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PLoS One 8(5):e64037
   Google Scholar
• Brito V, Puigdellívol M, Giralt A, et al.Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. Cell Death Dis 2013;18(4):e595
   Google Scholar
• Jovicic A, Zaldivar Jolissaint J, et al. MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms. PLoS One 2013;8(1):e54222
   PubMed Web of Science ®Google Scholar
• Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013;169(2):337-52
   PubMed Web of Science ®Google Scholar
• Khalatbary A. Olive oil phenols and neuroprotection. Nutr Neurosci 2013
   PubMed Web of Science ®Google Scholar
• Landwehrmeyer GB, Dubois B, de Yébenes JG. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62(3):262-72
   PubMed Web of Science ®Google Scholar
• Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005;65(2):286-92
   PubMed Web of Science ®Google Scholar
• Huntington Study Group TREND-HD Investigators Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008;65(12):1582-9
   PubMedGoogle Scholar
• Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009(3):CD006455
   Google Scholar
• Paulsen JS, Zimbelman JL, Hinton SC, et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am J Neuroradiol 2004;25(10):1715-21
   PubMed Web of Science ®Google Scholar
• Wild EJ, Tabrizi SJ. Predict-HD and the future of therapeutic trials. Lancet Neurol 2006;5(9):724-5
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11(1):42-53
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10(1):31-42
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12(7):637-49
   PubMed Web of Science ®Google Scholar
• Marder K, Gu Y, Eberly S, et al. Relationship of mediterranean diet and caloric intake to phenoconversion in huntington disease. JAMA Neurol 2013; doi: 10.1001/jamaneurol.2013.3487
   Web of Science ®Google Scholar
• Marder K, Zhao H, Eberly S, et al. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology 2009;73(5):385-92
   PubMed Web of Science ®Google Scholar
• Kopyov OV, Jacques S, Lieberman A, et al. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998;149(1):97-108
   PubMed Web of Science ®Google Scholar
• Bachoud-Levi A, Bourdet C, Brugieres P, et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 2000;161(1):194-202
   PubMed Web of Science ®Google Scholar
• Gaura V, Bachoud-Levi AC, Ribeiro MJ, et al. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 2004;127(Pt 1):65-72
   PubMedGoogle Scholar
• Bachoud-Levi AC, Gaura V, Brugieres P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006;5(4):303-9
   PubMed Web of Science ®Google Scholar
• Antoniades CA, Watts C. Huntington's disease and cell therapies: past, present, and future. Methods Mol Biol 1010:19-32
   PubMedGoogle Scholar
• Barker RA, Mason SL, Harrower TP, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry 2013;84(6):657-65
   PubMed Web of Science ®Google Scholar
• Cisbani G, Freeman TB, Soulet D, et al. Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. Brain 2013;136(Pt 2):433-43
   PubMedGoogle Scholar
• Benraiss A, Goldman SA. Cellular therapy and induced neuronal replacement for Huntington's disease. Neurotherapeutics 2011;8(4):577-90
   PubMed Web of Science ®Google Scholar
• Hendricks AE, Latourelle JC, Lunetta KL, et al. Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG). Am J Med Genet A 2009;149A(7):1375-81
   PubMed Web of Science ®Google Scholar
• Klitzman R, Thorne D, Williamson J, et al. Decision-making about reproductive choices among individuals at-risk for Huntington's disease. J Genet Couns 2007;16(3):347-62
   PubMedGoogle Scholar
• Richards FH, Rea G. Reproductive decision making before and after predictive testing for Huntington's disease: an Australian perspective. Clin Genet 2005;67(5):404-11
   PubMed Web of Science ®Google Scholar
• Tassicker RJ, Marshall PK, Liebeck TA, et al. Predictive and pre-natal testing for Huntington Disease in Australia: results and challenges encountered during a 10-year period (1994-2003). Clin Genet 2006;70(6):480-9
   PubMed Web of Science ®Google Scholar
• Labrune P. Pre-implantation genetic diagnosis of Huntington's chorea without disclosure if the parent “at risk” is affected. Arch Pediatr 2003;10(2):169-70
   PubMedGoogle Scholar
• Sermon K, Goossens V, Seneca S, et al. Preimplantation diagnosis for Huntington's disease (HD): clinical application and analysis of the HD expansion in affected embryos. Prenat Diagn 1998;18(13):1427-36
   PubMed Web of Science ®Google Scholar
• Bachoud-Levi AC, Remy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000;356(9246):1975-9
   PubMed Web of Science ®Google Scholar